Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Trivitron Healthcare...

    Trivitron Healthcare aims over Rs 1000 crore revenue in FY22

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-21T10:00:00+05:30  |  Updated On 21 Jan 2020 10:00 AM IST
    Trivitron Healthcare aims over Rs 1000 crore revenue in FY22

    "We are looking at a revenue of over Rs 1,000 crore for the fiscal year 2022. It will be achieved through organic and inorganic growth," Trivitron Healthcare Chairman and MD GSK Velu told.

    New Delhi: Domestic medical devices maker is looking to clock revenue of over Rs 1,000 crore in the fiscal year 2022 as it expands the number of manufacturing facilities and also eyes inorganic growth, a top company official has said. Trivitron Healthcare currently has nine manufacturing facilities across five locations - Chennai, Mumbai, Pune, Ankara and Helsinki -- and is in the process of constructing the tenth facility in Patalganga in Maharashtra.

    The company is expecting to close the current fiscal year with a revenue of around Rs 700 crore.

    "We are looking at a revenue of over Rs 1,000 crore for the fiscal year 2022. It will be achieved through organic and inorganic growth," Trivitron Healthcare Chairman and MD GSK Velu told.

    At present, 60 per cent of the company's revenue comes from India and 40 per cent is international, he added.

    "Going forward, Africa is going to be one of the biggest areas of growth for the company. We are also looking at both the US and China as key markets for growth this year and plan to have some kind of manufacturing presence in both the countries in the current calendar year," he added.

    A manufacturing presence in the US and China would strengthen the company's presence in the two of the most important markets globally, Velu said.

    Mostly, it would be through joint ventures with existing companies there, he said adding that the company already has a presence in these markets through trading infrastructure.

    At present the company is mainly in-vitro diagnostics, imaging, intensive care, operation theatres and renal dialysis segments, he added.

    "Out of these, in-vitro diagnostics and imaging contribute more than 85 per cent of our total revenues currently," Velu said.

    But going forward, the company is focusing on the areas like radiation protection and newborn screening, he said and added that it is also investing in research and development in mass spectrometry and radiation shielding.

    "The company is focusing on manufacturing and at present around 70 per cent of our revenues are coming from manufacturing," Velu said.

    Read also: Trivitron Healthcare eyes Rs 750 crore revenue in Financial Year 2019

    The company also has plans to list in FY23, but it would depend on many factors, he said.

    On being asked about the state of medical devices sector in India, Velu said, as the sector is different from the pharma sector, it should have the separate regulator and a separate department of medical devices to promote the segment.

    Read also: Trivitron Healthcare gets Ravish Mittal as new Group CFO

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok